Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

4 results about "Highly sensitive" patented technology

Method for solid-phase enrichment and mass spectrographic analysis of glycosylated peptide fragment

ActiveCN105300783AImprove Analytical Mass Spectrometry SelectivityHigh reaction specificityPreparing sample for investigationMaterial analysis by electric/magnetic meansGlycopeptideMass spectrometric
The invention belongs to the field of protein analysis, and relates to a new method for enrichment of a glycosylated peptide through a magnetic nanometer material modified by aminoxy, in particular to a method for solid-phase enrichment and mass spectrographic analysis of a glycosylated peptide fragment. The method comprises the following steps: firstly, using sodium periodate NaIO4 to oxidize a hydroxyl group on a glycopeptide to change the hydroxyl group to an aldehyde group; secondly, placing the magnetic nanometer material Fe3O4@ONH2 modified by aminoxy to an oxidized glycopeptide solution, and fixing the glycopeptide to the magnetic nanometer material through reaction of an aminoxy group and the aldehyde group obtained after a sugar chain in the glycopeptides is oxidized; thirdly, cleaning to remove non-glycopeptide which does not react with the nanometer material; finally, dissociating the captured glycopeptide from the material by use of sugar chain enzyme, and realizing mass spectrographic analysis of the glycosylated peptide. The method is simple in step, convenient to operate, high in speed and efficient, and can realize highly-sensitive and highly-selective mass spectrometric analysis of the glycosylated peptide.
Owner:FUDAN UNIV

MULTIPLEX ASSAY FOR DETERMINING beta-AMYLOID 42/40 RATIO IN HUMAN PLASMA SPECIMENS

PendingCN114072678APreparing sample for investigationDisease diagnosisMultiplexPhysiology
The present technology relates to methods for diagnosing, monitoring the progression of, assessing the efficacy of treatment of, or assessing risk for development of a neurodegenerative disorder in a patient. These methods are based on determining the ratio of beta-amyloid 42 ("A beta42") to beta- amyloid 40 ("A beta40") in a body fluid sample collected from a patient who has or is suspected of having a neurodegenerative disorder, using an improved and highly sensitive multiplex protein assay that simultaneously detects A beta42 and A beta40.
Owner:QUEST DIAGNOSTICS INVESTMENTS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products